Aberdeen, United Kingdom, January 10, 2017 – SIRAKOSS Ltd., a UK-based medical device company developing innovative bone grafting solutions for the $3 billion global orthopaedic
Berlin, Germany, 09 January 2017 – Eternygen GmbH, a privately owned Berlin-based metabolic diseases company, today announced the completion of its € 8.0 (approx. US$ 8.3)
Mironid’s ShoLo® and LoAc® programmes benefit from a close association with Dr George Muller as a key medicinal chemistry and experienced drug development advisor. George
C3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience
Glasgow, Scotland, and Sheffield, UK, 12th December 2016 – Mironid Ltd, a leader in cell signalling-directed drug development, and the University of Sheffield, announced today
Mironid is delighted to announce that Prof Albert Ong DM MA FRCP, Professor of Renal Medicine, Department of Infection Immunity & Cardiovascular Disease, University of
Louisville, Ky., December 2, 2016 – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present positive interim
Brighton, UK, November 10, 2016: Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment of
Epidarex is honored to have Elizabeth Roper, Partner, selected as one of the 50 Movers and Shakers in BioBusiness for 2016 from the Cambridge, UK-based
Originally published October 31, 2016 in Invest Edinburgh A new biotech company called Nodthera has been launched in Edinburgh to develop potential treatments for a